Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia - 20/08/11
, James R. Murphy, PhD d, Tim Byers, MD, MPH b, Ronald S. Gibbs, MD a, Margaret C. Neville, PhD a, Patricia C. Giclas, PhD e, Jane E. Salmon, MD f, V. Michael Holers, MD c
Reprints: Anne Lynch MB, BCh, BAO, MSPH, Department of Obstetrics and Gynecology, University of Colorado at Denver and Health Sciences Center, Department of Obstetrics and Gynecology, Mail Stop B198-5, Academic Office One, 12631 East 17th Avenue, PO Box 6511, Aurora, CO 80045.Résumé |
Objective |
Preeclampsia is a multisystem disease classically defined on the basis of hypertension and proteinuria. As shown in animal studies, complement activation is associated with inflammation in the placenta and adverse pregnancy outcomes. The association between complement activation in humans and adverse pregnancy outcomes is unclear. The purpose of this study was to determine whether elevated levels of the activation fragment Bb in early pregnancy are predictive of preeclampsia.
Study Design |
This prospective study of 701 women was conducted in Denver, CO. A single plasma sample was obtained from each woman before 20 weeks’ gestation. The cohort was followed up throughout pregnancy for the development of preeclampsia. Analysis included multivariate logistic regression to adjust for established risk factors for preeclampsia.
Results |
Preeclampsia developed in 4.6% of the cohort. Women with elevated Bb (90th or greater percentile) were substantially more likely to develop preeclampsia than women who had levels less than the 90th percentile (unadjusted relative risk [RR], 3.3, 95% confidence interval [CI] 1.6 to 7, P = .0009). Other significant risk factors for preeclampsia included nulliparity (RR, 2.1, 95% CI, 1-4), a high body mass index (P = .006 for trend), and maternal medical (preexisting maternal hypertension, type 1 diabetes, systemic lupus erythematosus) disease (RR, 4.4, 95% CI, 2-10). Significant risk factors among multiparous women included a history of hypertension in a previous pregnancy (RR, 5, 95% CI, 1.6 to 16) and a change of paternity (RR, 5.1, 95% CI, 1.6 to 15). Adjustment for risk factors did not attenuate the association between an elevated Bb and preeclampsia (adjusted odds ratio [OR], 3.8, 95% CI, 1.6 to 9, P = .002) in the cohort. After removing women with plasma obtained before 10 weeks, the adjusted OR of Bb in the top decile for preeclampsia was 6.1 (95% CI 2.2, 17, P = .0005).
Conclusion |
The complement activation product Bb in early pregnancy is a biomarker for elevated risk of preeclampsia. This observation suggests that events linked to activation of complement in early pregnancy are associated with the pathogenesis of preeclampsia.
Le texte complet de cet article est disponible en PDF.Key words : alternative complement pathway, complement activation fragment Bb, preeclampsia
Plan
| This study was supported by Grant K23 HD049684 from the National Institute of Child Health and Human Development and Newborn Hope Colorado (to A.M.L.) and National Institutes of Health Grant R01 AI 55007 (to V.M.H.). |
|
| Cite this article as: Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008;198:385.e1-385.e9. |
Vol 198 - N° 4
P. 385.e1-385.e9 - avril 2008 Retour au numéro
Article précédent
- Twin-to-twin transfusion syndrome: an antiangiogenic state?
- Juan Pedro Kusanovic, Roberto Romero, Jimmy Espinoza, Jyh Kae Nien, Chong Jai Kim, Pooja Mittal, Sam Edwin, Offer Erez, Francesca Gotsch, Shali Mazaki-Tovi, Nandor G. Than, Eleazar Soto, Natalia Camacho, Ricardo Gomez, Ruben Quintero, Sonia S. Hassan
- Intrahepatic vein for fetal blood sampling: one center’s experience
- Abimbola J. Aina-Mumuney, Cynthia J. Holcroft, Karin J. Blakemore, Jessica L. Bienstock, Nancy A. Hueppchen, Lorraine A. Milio, Jude P. Crino
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?